State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 2,563,226 shares of Avalo Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: State Street Corporation reported aggregate beneficial ownership of 2,563,226 shares of Avalo Therapeutics Inc. common stock.
  • Percent of class: The reported stake represents 4.8% of the class of common stock (CUSIP 05338F306).
  • Shared voting power: State Street disclosed shared voting power over 2,490,708 shares, with sole voting power of 0.
  • Shared dispositive power: Shared dispositive power covers all 2,563,226 shares, with sole dispositive power of 0.
  • Filing type: The statement was filed as a parent holding company (type HC), with five named subsidiaries classified as investment advisers (IA) listed as the relevant entities that acquired the securities.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026.

State Street's Schedule 13G Ownership Disclosure for Avalo Therapeutics

According to the filing, State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, submitted a Schedule 13G disclosing its beneficial ownership position in Avalo Therapeutics Inc., whose principal executive offices are listed at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania, 19087. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026, and covers ownership as of September 30, 2026.

The filing identifies State Street as a parent holding company, with the following subsidiaries listed as the entities that acquired the reported securities: SSGA Funds Management, Inc. (IA); State Street Global Advisors Europe Limited (IA); State Street Global Advisors Limited (IA); State Street Global Advisors Trust Company (IA); and State Street Global Advisors, Ltd. (IA). All five are classified as investment advisers in the filing.

State Street disclosed zero sole voting power and zero sole dispositive power over the shares. The filing notes shared voting power of 2,490,708 shares and shared dispositive power of 2,563,226 shares, equaling the total aggregate beneficial ownership figure. The filing also includes a certification that, according to the registrant, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

What Was Disclosed

State Street Corporation disclosed through a Schedule 13G that it beneficially owns 2,563,226 shares, or 4.8%, of Avalo Therapeutics Inc. common stock as of September 30, 2026, held through five investment adviser subsidiaries with shared but no sole voting or dispositive power.